AZAB MOHAMMAD
Known title: DirectorCIK: 0001309653
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Xenon (XENE) sees insider buying and new analyst price target. Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).
Transaction History
| LSTA | ▲ Buy | Grant | 30,456 | $0 | 1/9/2026 | View on chart |
| LSTA | ▲ Buy | Grant | 15,789 | $0 | 1/9/2025 | View on chart |
| LSTA | ▲ Buy | Grant | 19,480 | $0 | 1/9/2024 | View on chart |
| XENE | ▲ Buy | Option Exercise | 823 | $8K | 12/19/2023 | View on chart |
| XENE | ▲ Buy | Option Exercise | 3,497 | $34K | 12/19/2023 | View on chart |
| LSTA | ▲ Buy | Grant | 20,000 | $0 | 1/9/2023 | View on chart |
| XENE | ▲ Buy | Option Exercise | 3,086 | $8K | 12/12/2022 | View on chart |
| LSTA | ▲ Buy | Grant | 19,200 | $120K | 9/15/2022 | View on chart |
| XENE | ▲ Buy | Option Exercise | 3,086 | $11K | 12/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Lisata reports first patient dose in MAR002 acromegaly trial
Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.
Lisata reports first patient dose in MAR002 acromegaly trial. Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.